Hostname: page-component-586b7cd67f-2brh9 Total loading time: 0 Render date: 2024-11-22T07:16:45.937Z Has data issue: false hasContentIssue false
  • English
  • Français

Controlled Evaluation of Nicotinamide Adenine Dinucleotide in the Treatment of Chronic Schizophrenic Patients

Published online by Cambridge University Press:  29 January 2018

N. S. Kline ,
G. L. Barclay ,
J. O. Cole ,
A. H. Esser ,
H. Lehmann  and
J. R. Wittenborn
N. S. Kline
Affiliation:
Research Center, Rockland State Hospital, Orangeburg, New York
G. L. Barclay
Affiliation:
Department of Mental Hygiene, State of New York
J. O. Cole
Affiliation:
National Institute of Mental Health, Bethesda, Maryland
A. H. Esser
Affiliation:
Research Ward, Research Center, Rockland State Hospital, Orangeburg, New York
H. Lehmann
Affiliation:
Douglas Hospital, McGill University, Montreal, Canada
J. R. Wittenborn
Affiliation:
Interdisciplinary Research Center, Rutgers, The State University, New Brunswick, New Jersey
Get access Rights & Permissions [Opens in a new window]

Extract

On 30 March, 1966, at the Symposium “Enzymes in Mental Health” sponsored by the Carl Neuberg Society for International Scientific Relations, A. Hoffer (1) described the apparently successful treatment in 13 of 17 (acute and chronic) schizophrenic patients in 3 to 5 days by the daily oral use of 1 to 2 grams of nicotinamide adenine dinucleotide (NAD), better known as diphosphopyridinenucleotide (DPN). Widespread publicity given to this announcement attests to the need of more effective treatment for this illness. It also occasioned frequent and persistent inquiry from schizophrenic patients and their relatives as to the suitability of this treatment in their own instance. Rapid confirmation of the findings would justify widespread efforts to evaluate this preparation, whereas failure of confirmation would provide reasonable grounds for a more cautious approach to its use. The members of the Council of the American College of Neuropsycho-pharmacology decided that, as a group of impartial scientists, it would be appropriate for them to carry out such an investigation as rapidly as was compatible with adequate determination of the usefulness of the preparation.

Type
Research Article
Information
The British Journal of Psychiatry , Volume 113 , Issue 500 , July 1967 , pp. 731 - 742
Copyright
Copyright © Royal College of Psychiatrists, 1967 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Hoffer, A. (1966). As quoted in the New York Times, 31 March.Google Scholar
2. Hoffer, A. (1966). Personal communication.Google Scholar
3. Wittenborn, J. R. (1962). “The dimensions of psychosis.” J. nerv. ment. Dis., 134, 117–128.Google Scholar
4. Hoffer, A., and Osmond, H. (1961). “A card sorting test helpful in making psychiatric diagnosis.” J. Neuropsychiat., 2, 306.Google Scholar
5. Overall, J. E., and Gorham, D. R. (1962). “The brief psychiatric rating scale.” Psychol. Reports, 10, 799–812.Google Scholar
6. Chapple, E. D., Chamberlain, A. S., Esser, A. H., and Kline, N. S. (1963). “The measurement of activity patterns of schizophrenic patients.” J. nerv. ment. Dis., 136, 258–267.Google Scholar
7. Hoffer, A. (1966). In a letter to Dr. N. S. Kline.Google Scholar
8. Gallant, D. M., Bishop, M. P., and Steele, C. A. (1966). “DPN (NAD-oxidized form): a preliminary evaluation in chronic schizophrenic patients.” Current Therapeutic Research, 8, 542.Google Scholar
9. O?Hollaren, P. (1961). “Diphosphopyridinc nucleotide in the prevention, diagnosis and treatment of problem drinkers.” West. J. Surg., Obst. and Gynec, 213–215.Google Scholar
10. Gottlieb, J. S. (1966). Personal communication.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.